Newsstand | Aplastic Anemia and MDS International Foundation

Newsstand

Here's where you'll find a regularly updated, broad range of articles written by the AAMDSIF team, allied health organizations and news organizations. By staying well-informed, patients and families are practicing a form of self-support that will help them be more effective self-advocates when engaging with health care providers.

Immunotherapies for the treatment of AML

Originally Published: 08/14/2018
Description: Gemtuzumab ozogamicin is a monoclonal antibody drug for the treatment of acute myeloid leukemia (AML). This drug uses a different strategy to classical chemotherapeutic agents, and the development of other similar drugs is expected to drastically improve the outcomes of patients with AML. In this interview, Chrisoph Röllig, MD, from the University Hospital Carl Gustav Carus, Dresden, Germany, also discusses treatments that have recently received FDA approval, such as CPX-351, a liposomal formulation of cytarabine and daunorubicin that has been approved for the treatment of...

MDS Update, July 2018

Originally Published: 07/25/2018

NIH and VA collaborate to boost veterans’ access to cancer clinical trials

Originally Published: 07/11/2018
Veterans with cancer who receive treatment from the Department of Veterans Affairs (VA) will now have easier access to clinical trials of novel cancer treatments, thanks to an agreement between VA and the National Cancer Institute (NCI), part of the National Institutes of Health.  

Research Reveals New Treatment Approach For Acute Myeloid Leukemia

Originally Published: 06/15/2018
According to a story from med.miami.edu, a team of researchers working at the Sylvester Comprehensive Cancer Center, which is part of the University of Miami School of Medicine, made a significant discovery that could lead to a new approach to treating acute myeloid leukemia. Data from their research revealed than inhibiting an enzyme called CARM1 (also known as PRMT4) was able to slow down the progression of acute myeloid leukemia. In addition, this action was able to achieve this effect without affecting the production of healthy blood.

2018 AAMDSIF Scientific Symposium Patient Summary

Originally Published: 06/06/2018
The AAMDSIF 2018 Scientific Symposium Patient Summary is now available in print format. Containing 30 lay language summaries of presentations from a panel of international experts, this 28-page publication presents the latest  in bone marrow failure research. Order your copy by contacting orders@aamds.org. Supply is limited

New hope for people with AML – an interview with Kathleen Weis, CEO of the Aplastic Anemia and MDS International Foundation

Originally Published: 06/06/2018
Don’t give up hope, because the chances of finding a cure for acute myeloid leukemia (AML) are improving every day. That’s the message from Kathleen Weis, CEO of the Aplastic Anemia and MDS International Foundation (AAMDSIF), to those living with this rare blood and bone marrow cancer, following this year’s AML World Awareness Day.

Early, Attenuated-Dose Hypomethylating Agent Therapy May Be Effective in Low-Risk MDS

Originally Published: 05/31/2018
Attenuated doses of hypomethylating agents (HMA) early in treatment could improve outcomes among transfusion independent patients with lower-risk myelodysplastic syndromes (MDS), according to findings that will be presented at the American Society of Clinical Oncology 2018 Annual Meeting in Chicago, Illinois.1

Emergency Supply List

Originally Published: 05/30/2018
Handy list to keep for potential evacuations.   From FEMA

Bedside art therapy benefits blood cancer patients

Originally Published: 04/23/2018
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including those undergoing transplant.

Dynamics of DNMT3A mutation and prognostic relevance in patients with primary myelodysplastic syndrome

Originally Published: 04/02/2018
Background DNMT3A gene mutation has been associated with poor prognosis in acute myeloid leukemia, but its clinical implications in myelodysplastic syndrome (MDS) and dynamic changes during disease progression remain controversial.